Yajun Xue
Latest contributions
Renal denervation in China: momentum, insights, and evolution
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session highlights the rapidly evolving clinical experience of renal denervation (RDN) in China following regulatory approval, with a focus on real-world practice and programme development.
It reviews how structured, patient-centred hypertension pathways are being integrated with RDN, alongside practical strategies for managing complex renal...
Advancing renal denervation in China: from guidelines to practice
20 May 2025 – From EuroPCR 2025
Discover how renal denervation (RDN) is rapidly evolving in China to meet the needs of patients with uncontrolled hypertension. This EuroPCR 2025 session highlights recent guideline endorsements and approvals, patient selection based on drug resistance and cardiovascular risk, and the critical role of diagnostic screening. Gain...
